Melatonin as a principal component of red light therapy

Ronnie L. Yeager, Deanna A. Oleske, Ruth A. Sanders, John B. Watkins, Janis T. Eells, Diane S. Henshel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Melatonin is well recognized for its role as a potent antioxidant and is directly implicated in the free radical theory of aging [1] [Reiter RJ, Pablos MI, Agapito TT, Guerrero JM. Melatonin in the context of the free radical theory of aging. Ann N Y Acad Sci 1996;786:362-78]. Moreover, melatonin has been shown to retard age-related increases in lipid peroxidation and oxidative damage [2] [Okatani Y, Wakatsuki A, Reiter RJ. Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerated mice. J Pineal Res 2002;32:143-8] and to act directly upon the immune system [3] [Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals 1994;3:107-17]. This report focuses on characterizing documented functions of melatonin in the context of red light therapy and proposes that melatonin is a potential mediator of red light's therapeutic effects, a hypothesis that is as yet untested. Red light therapy (670 nm, 4 J/cm2) has been shown to restore glutathione redox balance upon toxicological insult and enhance both cytochrome c oxidase and energy production, all of which may be affected by melatonin. The red light treatment has also been successfully implemented in the clinical setting for its effectiveness in reducing both the number of incidences and severity of oral mucositis resulting in part from the chemotherapy and/or radiation administered prior to bone marrow transplants. Moreover, red light therapy improves wound healing and is being further tested for its ability to ameliorate toxicant-induced retinal and visual cortical neuron damage. Researchers in the growing field of light therapy may be in a position to draw from and collaborate with melatonin researchers to better characterize this alternative treatment.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalMedical Hypotheses
Volume69
Issue number2
DOIs
StatePublished - 2007

Fingerprint

Phototherapy
Melatonin
Free Radicals
Immune System
Research Personnel
Stomatitis
Therapeutic Uses
Electron Transport Complex IV
Electron Transport
Wound Healing
Toxicology
Lipid Peroxidation
Oxidation-Reduction
Glutathione
Antioxidants
Bone Marrow
Radiation
Transplants
Neurons
Light

ASJC Scopus subject areas

  • Developmental Biology
  • Medicine(all)
  • Drug Discovery

Cite this

Yeager, R. L., Oleske, D. A., Sanders, R. A., Watkins, J. B., Eells, J. T., & Henshel, D. S. (2007). Melatonin as a principal component of red light therapy. Medical Hypotheses, 69(2), 372-376. https://doi.org/10.1016/j.mehy.2006.12.041

Melatonin as a principal component of red light therapy. / Yeager, Ronnie L.; Oleske, Deanna A.; Sanders, Ruth A.; Watkins, John B.; Eells, Janis T.; Henshel, Diane S.

In: Medical Hypotheses, Vol. 69, No. 2, 2007, p. 372-376.

Research output: Contribution to journalArticle

Yeager, RL, Oleske, DA, Sanders, RA, Watkins, JB, Eells, JT & Henshel, DS 2007, 'Melatonin as a principal component of red light therapy', Medical Hypotheses, vol. 69, no. 2, pp. 372-376. https://doi.org/10.1016/j.mehy.2006.12.041
Yeager RL, Oleske DA, Sanders RA, Watkins JB, Eells JT, Henshel DS. Melatonin as a principal component of red light therapy. Medical Hypotheses. 2007;69(2):372-376. https://doi.org/10.1016/j.mehy.2006.12.041
Yeager, Ronnie L. ; Oleske, Deanna A. ; Sanders, Ruth A. ; Watkins, John B. ; Eells, Janis T. ; Henshel, Diane S. / Melatonin as a principal component of red light therapy. In: Medical Hypotheses. 2007 ; Vol. 69, No. 2. pp. 372-376.
@article{47dffe03a1ae446894ef4d2c8f864576,
title = "Melatonin as a principal component of red light therapy",
abstract = "Melatonin is well recognized for its role as a potent antioxidant and is directly implicated in the free radical theory of aging [1] [Reiter RJ, Pablos MI, Agapito TT, Guerrero JM. Melatonin in the context of the free radical theory of aging. Ann N Y Acad Sci 1996;786:362-78]. Moreover, melatonin has been shown to retard age-related increases in lipid peroxidation and oxidative damage [2] [Okatani Y, Wakatsuki A, Reiter RJ. Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerated mice. J Pineal Res 2002;32:143-8] and to act directly upon the immune system [3] [Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals 1994;3:107-17]. This report focuses on characterizing documented functions of melatonin in the context of red light therapy and proposes that melatonin is a potential mediator of red light's therapeutic effects, a hypothesis that is as yet untested. Red light therapy (670 nm, 4 J/cm2) has been shown to restore glutathione redox balance upon toxicological insult and enhance both cytochrome c oxidase and energy production, all of which may be affected by melatonin. The red light treatment has also been successfully implemented in the clinical setting for its effectiveness in reducing both the number of incidences and severity of oral mucositis resulting in part from the chemotherapy and/or radiation administered prior to bone marrow transplants. Moreover, red light therapy improves wound healing and is being further tested for its ability to ameliorate toxicant-induced retinal and visual cortical neuron damage. Researchers in the growing field of light therapy may be in a position to draw from and collaborate with melatonin researchers to better characterize this alternative treatment.",
author = "Yeager, {Ronnie L.} and Oleske, {Deanna A.} and Sanders, {Ruth A.} and Watkins, {John B.} and Eells, {Janis T.} and Henshel, {Diane S.}",
year = "2007",
doi = "10.1016/j.mehy.2006.12.041",
language = "English",
volume = "69",
pages = "372--376",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Melatonin as a principal component of red light therapy

AU - Yeager, Ronnie L.

AU - Oleske, Deanna A.

AU - Sanders, Ruth A.

AU - Watkins, John B.

AU - Eells, Janis T.

AU - Henshel, Diane S.

PY - 2007

Y1 - 2007

N2 - Melatonin is well recognized for its role as a potent antioxidant and is directly implicated in the free radical theory of aging [1] [Reiter RJ, Pablos MI, Agapito TT, Guerrero JM. Melatonin in the context of the free radical theory of aging. Ann N Y Acad Sci 1996;786:362-78]. Moreover, melatonin has been shown to retard age-related increases in lipid peroxidation and oxidative damage [2] [Okatani Y, Wakatsuki A, Reiter RJ. Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerated mice. J Pineal Res 2002;32:143-8] and to act directly upon the immune system [3] [Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals 1994;3:107-17]. This report focuses on characterizing documented functions of melatonin in the context of red light therapy and proposes that melatonin is a potential mediator of red light's therapeutic effects, a hypothesis that is as yet untested. Red light therapy (670 nm, 4 J/cm2) has been shown to restore glutathione redox balance upon toxicological insult and enhance both cytochrome c oxidase and energy production, all of which may be affected by melatonin. The red light treatment has also been successfully implemented in the clinical setting for its effectiveness in reducing both the number of incidences and severity of oral mucositis resulting in part from the chemotherapy and/or radiation administered prior to bone marrow transplants. Moreover, red light therapy improves wound healing and is being further tested for its ability to ameliorate toxicant-induced retinal and visual cortical neuron damage. Researchers in the growing field of light therapy may be in a position to draw from and collaborate with melatonin researchers to better characterize this alternative treatment.

AB - Melatonin is well recognized for its role as a potent antioxidant and is directly implicated in the free radical theory of aging [1] [Reiter RJ, Pablos MI, Agapito TT, Guerrero JM. Melatonin in the context of the free radical theory of aging. Ann N Y Acad Sci 1996;786:362-78]. Moreover, melatonin has been shown to retard age-related increases in lipid peroxidation and oxidative damage [2] [Okatani Y, Wakatsuki A, Reiter RJ. Melatonin protects hepatic mitochondrial respiratory chain activity in senescence-accelerated mice. J Pineal Res 2002;32:143-8] and to act directly upon the immune system [3] [Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals 1994;3:107-17]. This report focuses on characterizing documented functions of melatonin in the context of red light therapy and proposes that melatonin is a potential mediator of red light's therapeutic effects, a hypothesis that is as yet untested. Red light therapy (670 nm, 4 J/cm2) has been shown to restore glutathione redox balance upon toxicological insult and enhance both cytochrome c oxidase and energy production, all of which may be affected by melatonin. The red light treatment has also been successfully implemented in the clinical setting for its effectiveness in reducing both the number of incidences and severity of oral mucositis resulting in part from the chemotherapy and/or radiation administered prior to bone marrow transplants. Moreover, red light therapy improves wound healing and is being further tested for its ability to ameliorate toxicant-induced retinal and visual cortical neuron damage. Researchers in the growing field of light therapy may be in a position to draw from and collaborate with melatonin researchers to better characterize this alternative treatment.

UR - http://www.scopus.com/inward/record.url?scp=34249653046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249653046&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2006.12.041

DO - 10.1016/j.mehy.2006.12.041

M3 - Article

C2 - 17321060

AN - SCOPUS:34249653046

VL - 69

SP - 372

EP - 376

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 2

ER -